Insmed (INSM) Q3 Earnings: How Key Metrics Compare to Wall Street EstimatesZacks Investment Research • Thursday
Insmed Reports Third-Quarter 2026 Financial Results and Provides Business UpdatePRNewsWire • Thursday
Insmed (INSM) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseZacks Investment Research • 10/22/26
Insmed Launches BRINSUPRI® Tablets 25 mg (brensocatib hydrate) for the Treatment of Non-Cystic Fibrosis Bronchiectasis in JapanPRNewsWire • 10/19/26
Insmed Features the Global Phase 3 PALM Clinical Development Program Evaluating Treprostinil Palmitil Inhalation Powder (TPIP) at CHEST 2026PRNewsWire • 10/15/26
Insmed to Present New Data Across Its Respiratory Portfolio at CHEST 2026 and IDWeek 2026PRNewsWire • 10/14/26
FDA Grants Priority Review to Insmed's sNDA for ARIKAYCE® (amikacin liposome inhalation suspension) for Treatment of MAC Lung Disease With PDUFA Target Action Date Set for January 28, 2027PRNewsWire • 09/21/26
Insmed Incorporated (INSM) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/15/26
Insmed Incorporated (INSM) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference TranscriptSeeking Alpha • 09/09/26
Insmed to Present Data Across Its Respiratory Portfolio, Including New Late-Breaking ARIKAYCE® (amikacin liposome inhalation suspension) Results From Phase 3b ENCORE Study at the European Respiratory Society Congress 2026PRNewsWire • 09/03/26